CABA Stock Chart & Stats
$50.00
$0.00(0.00%)
At close: 4:00 PM EDT
$50.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$35.00 - $67.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$9.99B
Enterprise Value$270.72
Total Cash (Recent Filing)$225.10M
Total Debt (Recent Filing)$25.71M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Nov 05, 2026EPS Estimate
-5.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding169,545,440
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-1.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$247.86Price Target Upside395.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-23.17
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Autoimmune CAR T PipelineA focused pipeline targeting B cell-mediated autoimmune diseases gives Cabaletta a coherent therapeutic strategy and specialized development identity. Concentrating resources on related indications may support platform learning and efficient expansion across diseases if clinical development succeeds.
Low Financial LeverageLow leverage reduces fixed financial obligations and preserves balance-sheet flexibility while the company advances costly clinical programs. The relatively modest debt burden may leave more financing and strategic options available than a highly leveraged structure would allow during development.
Expanded Financing FlexibilityThe larger authorized share base gives Cabaletta greater capacity to raise equity or support strategic initiatives as programs progress. Although issuance could dilute shareholders, this structural flexibility can help fund research, clinical execution, partnerships, or other corporate priorities.
Bears Say
No Commercial RevenueCabaletta remains pre-revenue, so it has no recurring commercial sales base to fund operations or validate market demand. Continued dependence on development financing makes future progress reliant on successful clinical execution and eventual product approval rather than established operating cash generation.
Widening Operating LossesThe substantial expansion in losses indicates that development spending and operating costs are increasing faster than any offsetting revenue. Persistent negative profitability reduces internal funding capacity and raises the amount of capital required before potential therapies can become commercial products.
Severe Cash Burn And Funding DependenceCash outflows of this magnitude consume resources directly and imply continued financing needs to sustain research and clinical programs. Because free cash flow closely tracks net loss, the losses are translating into real cash depletion, increasing exposure to future capital-raising requirements.
Cabaletta Bio News
CABA FAQ
What was Cabaletta Bio’s price range in the past 12 months?
Cabaletta Bio lowest stock price was $35.00 and its highest was $67.00 in the past 12 months.
What is Cabaletta Bio’s market cap?
Cabaletta Bio’s market cap is $9.99B.
When is Cabaletta Bio’s upcoming earnings report date?
Cabaletta Bio’s upcoming earnings report date is Nov 05, 2026 which is in 58 days.
How were Cabaletta Bio’s earnings last quarter?
Cabaletta Bio released its earnings results on Aug 13, 2026. The company reported -$5.792 earnings per share for the quarter, beating the consensus estimate of -$6.354 by $0.562.
Is Cabaletta Bio overvalued?
According to Wall Street analysts Cabaletta Bio’s price is currently Undervalued.
Does Cabaletta Bio pay dividends?
Cabaletta Bio does not currently pay dividends.
What is Cabaletta Bio’s EPS estimate?
Cabaletta Bio’s EPS estimate is -5.4.
How many shares outstanding does Cabaletta Bio have?
Cabaletta Bio has 169,545,440 shares outstanding.
What happened to Cabaletta Bio’s price movement after its last earnings report?
Cabaletta Bio reported an EPS of -$5.792 in its last earnings report, beating expectations of -$6.354. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cabaletta Bio?
Currently, no hedge funds are holding shares in MX:CABA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cabaletta Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$247.86 (395.72% Upside)
$247.86 (395.72% Upside)
Blogger Sentiment
Bullish
MX:CABA Sentiment 100%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
125.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.36%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cabaletta Bio
Cabaletta Bio, Inc. is a biotechnology firm in the clinical development stage, specializing in the invention and advancement of sophisticated engineered T cell therapies. Its core mission is to treat autoimmune diseases where B cells are implicated in producing harmful autoantibodies. The company's unique chimeric autoantibody receptor (CAAR) T cell platform is engineered to precisely target and eradicate these specific disease-causing B cells. Leading its pipeline is DSG3-CAART, which is currently in Phase I clinical trials. This candidate is being assessed for efficacy in two distinct conditions: mucosal pemphigus vulgaris, an autoimmune blistering skin disorder, and Hemophilia A in patients exhibiting Factor VIII alloantibodies. Cabaletta's broader product candidate portfolio also includes MuSK-CAART, a preclinical asset aimed at a particular subset of myasthenia gravis patients; FVIII-CAART, in the discovery phase for another subgroup of Hemophilia A sufferers; and DSG3/1-CAART, also a discovery-stage program, designed for mucocutaneous pemphigus vulgaris. The company maintains strategic alliances, including a collaboration with the University of Pennsylvania and a research pact with The Regents of the University of California. Founded in 2017 as Tycho Therapeutics, Inc., it adopted the name Cabaletta Bio, Inc. in August 2018 and is based in Philadelphia, Pennsylvania.
CABA Stock 12 Month Forecast
Average Price Target
$247.86
▲(395.72% Upside)